Health Condition 1: K77- Liver disorders in diseases classified elsewhere
Conditions
Interventions
Intervention1: Low dose terlipressin plus noradrenalin arm: Terlipressin 0.25 mg 6 Hrly iv bolus, fixed dose • Noradrenaline, which would be given as a continuous infusion at a starting dose of 0.1µg/
Sponsors
Non sponsered
Eligibility
Inclusion criteria
Inclusion criteria: ACLF as per APASL criteria AKI at admission as defined by ICA-AKI criteria HRS-AKI grade II & grade III as defined by ICA 12 hour of admission
Exclusion criteria
Exclusion criteria: Age 70 years Septic shock Patient with HCC outside Milan’s criteria Severe Hyponatremia (Na Patients with RH failure, CAD, PVD, arrhythmias and cardiomyopathy Pregnancy or Lactating mother Grade III/IV HE or Shock requiring inotropes or patients on mechanical ventilator at time of randomization In-hospital new AKI Active urinary sediments – 2+ albumin or above, dysmorphic RBCs Known CKD, obstructive uropathy Lack of informed consent Prior intolerance or S/E to Terlipressin or albumin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AKI reversal by day 7Timepoint: AKI reversal by day 7 | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of Partial/1 stage regression of AKI at 48 hour Complete reversal of HRS maximum by day 15 Liver transplantation Mortality at day 28, day 90 Progression or resolution of OFs Treatment related adverse effects & their gradesTimepoint: 90 days | — |
Countries
India
Contacts
Public ContactChandan kumar
Institute of liver and biliary sciences
Outcome results
None listed